ReviewChinese medicine2020
Panax ginseng C. A. Meyer as a potential therapeutic agent for organ fibrosis disease.
Review in Chinese medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Ginseng as a Functional Food Intervention for Interstitial Lung Disease: A Review of the Benefits and Molecular Mechanisms.Food science & nutrition · 2026Review
- Phytochemicals with potential NMDAR-inhibitory activities: a review of neuroprotective mechanisms against excitotoxicity.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
- Challenges and opportunities for ginseng-based medicines in treating cardiac fibrosis from mechanistic insights to clinical translation.Chinese herbal medicines · 2026Review
- Jiawei Danggui Buxue Decoction Reduces Apoptosis and EMT of Renal Interstitial Fibrosis by Regulating JAK2/STAT3 Signaling Pathway.Combinatorial chemistry & high throughput screening · 2026Article
- Protective effects of ginsenosides in cerebral small vessel disease: Cellular and molecular mechanisms.Journal of ginseng research · 2025Review
- Heterologous Expression of Recombinant Ginseng Tetradecapeptide inFoods (Basel, Switzerland) · 2025Article
- Liver disorders and phytotherapy.Toxicology reports · 2025Review
- Potential of herbal formulas and bioactive metabolites in treating atherosclerosis: targeted modulation of macrophage polarization.Frontiers in pharmacology · 2025Review
- Anti-Fibrosis Effect ofNutrients · 2024Article
- Ginseng saponin metabolite 20(S)-protopanaxadiol relieves pulmonary fibrosis by multiple-targets signaling pathways.Journal of ginseng research · 2023Article
- Identification of the Main Chemical constituents and mechanism of Renshen Guben oral liquid against Renal Fibrosis.Chinese medicine · 2023Article
- A Meta-Analysis of Preclinical Studies to Investigate the Effect ofAntioxidants (Basel, Switzerland) · 2023Review
- Discrepancy Study of the Chemical Constituents of Panax Ginseng from Different Growth Environments with UPLC-MS-Based Metabolomics Strategy.Molecules (Basel, Switzerland) · 2023Article
- Ginsenoside Rg3 attenuates pulmonary fibrosis by inhibiting endothelial to mesenchymal transition.Animal cells and systems · 2023Article
- Effects of natural products on skin inflammation caused by abnormal hormones secreted by the adrenal gland.Frontiers in pharmacology · 2023Review
- Anticancer properties and pharmaceutical applications of ginsenoside compound K: A review.Chemical biology & drug design · 2022Review
- Multi-Pharmaceutical Activities of Chinese Herbal Polysaccharides in the Treatment of Pulmonary Fibrosis: Concept and Future Prospects.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundGinseng (Panax ginseng C. A. Meyer), a representative Chinese herbal medicine, can improve the body's antioxidant and anti-inflammatory capacity. Recently, scientists have shifted emphasis towards the initial stages of different malignant diseases-corresponding organ fibrosis and explored the essential role of P. ginseng in the treatment of fibrotic diseases. MAIN BODY: In the first instance, the review generalizes the molecular mechanisms and common therapeutic methods of fibrosis. Next, due to the convenience and safety of individual medication, the research progress of ginseng extract and formulas in treating liver fibrosis, pulmonary fibrosis, myocardial fibrosis, and renal fibrosis has been systematically summarized. Finally, we describe active ingredients isolated from P. ginseng for their outstanding anti-fibrotic properties and further reveal the potential therapeutic prospect and limitations of P. ginseng in fibrotic diseases.
conclusionsP. ginseng can be regarded as a valuable herbal medicine against fibrous tissue proliferation. Ginseng extract, derived formulas and monomers can inhibit the abundant deposition of extracellular matrix which caused by repeated damage and provide protection for fibrotic organs. Although the molecular mechanisms such as transforming growth factor β signal transduction have been confirmed, future studies should still focus on exploring the underlying mechanisms of P. ginseng in treating fibrotic disease including the therapeutic targets of synergistic action of multiple components in P. ginseng. Moreover, it is also necessary to carry out clinical trial to evaluate the feasibility of P. ginseng in combination with common fibrosis drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.